Steady-State Study of Extended Phenytoin Sodium Capsules 100 mg and Dilantin® Kapseals® 100 mg
Status:
Completed
Trial end date:
2005-12-01
Target enrollment:
Participant gender:
Summary
The objective of this study was to investigate the steady-state bioequivalence of Mylan's
extended phenytoin sodium capsules, 100mg (3x100mg), to Pfizer's Dilantin® Kapseals®, 100mg
(3x100mg), under both fasting and fed conditions.